U.S. Markets close in 3 hrs 55 mins

GlycoMimetics, Inc. (GLYC)

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
Add to watchlist
14.19+0.59 (+4.34%)
As of 12:04PM EDT. Market open.
People also watch
AKBAGNCADRNALOXOAKAO

GlycoMimetics, Inc.

9708 Medical Center Drive
Rockville, MD 20850
United States
240-243-1201
http://www.glycomimetics.com

SectorHealthcare
IndustryBiotechnology
Full Time Employees42

Key Executives

NameTitlePayExercisedAge
Mrs. Rachel K. KingChief Exec. Officer and Director772.42kN/A58
Mr. Brian M. HahnChief Financial Officer and Sec.458.38kN/A43
Dr. John L. Magnani Ph.D.Chief Scientific Officer, Sr. VP of Research and Director529.58kN/A64
Dr. Helen M. Thackray M.D., FAAPChief Medical Officer and Sr. VP of Clinical Devel.577.27kN/A49
Mr. Henry FlannerVP of Technical OperationsN/AN/AN/A
Amounts are as of December 31, 2016 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

GlycoMimetics, Inc., a clinical stage biotechnology company, focuses on the discovery and development of glycomimetic drugs to address unmet medical needs resulting from diseases in the United States. The company is developing its lead product candidates include rivipansel, a pan-selectin antagonist, which is in Phase III clinical trials for the treatment of vaso-occlusive crisis, a debilitating and painful condition that occurs periodically throughout the life of a person with sickle cell disease; and GMI-1271, an E-selectin antagonist to treat acute myeloid leukemia and other hematologic cancers. It is also developing GMI-1359, a drug candidate targeting E-selectin and CXCR4; and galectin-3 and galectin-9 inhibitors. The company has a collaborative research and development agreement with Pfizer Inc. GlycoMimetics, Inc. was founded in 2003 and is headquartered in Rockville, Maryland.

Corporate Governance

GlycoMimetics, Inc.’s ISS Governance QualityScore as of September 1, 2017 is 9. The pillar scores are Audit: 1; Board: 9; Shareholder Rights: 8; Compensation: 9.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.